Rhonda Farnum, SVP, COMM & MEDICAL AFFAIRS at Theravance Biopharma, Inc. (TBPH), sold 2,356 shares at $10.16 ($24K) on 2022-02-28, disclosed to the SEC on 2022-03-02.
Scheduled sale ($24k) by SVP, COMM & MEDICAL AFFAIRS under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| Filing → |
| TBPH | SELL | 2026-03-18 | $650K | — | Filing → |
| TBPH | SELL | 2025-12-05 | $1.2M | — | Filing → |
| TBPH | SELL | 2025-07-16 | $174K | — | Filing → |